Carmine N. Stengone
Known title: CEO and PresidentCIK: 0001861519
Carmine N. Stengone's purchase track record
Carmine N. Stengone has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2024 | KPRX | $5K | -2.0% | -8.9% | +0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CTNM | ▲ Buy | Option Exercise | 2,500 | $3K | 9/8/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 2,500 | $41K | 9/8/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 2,500 | $3K | 8/3/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 2,500 | $40K | 8/3/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 2,500 | $3K | 7/8/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 2,500 | $40K | 7/8/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 7,500 | $8K | 6/30/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 2,500 | $3K | 6/30/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 10,000 | $160K | 6/30/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 2,700 | $3K | 2/25/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 2,700 | $43K | 2/25/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 4,400 | $6K | 2/24/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 4,400 | $70K | 2/24/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 400 | $504 | 2/11/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 400 | $6K | 2/11/2026 | View on chart |
| KPRX | ▲ Buy | Open Market | 1,250 | $5K | 9/11/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
CTNM Depressed After Phase 2 Miss
Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.
CTNM Depressed After Phase 2 Miss. Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.